Serum osteoprotegerin and sex steroid levels in patients with prostate cancer

Journal of Andrology

Volumn 33, Issue 4, 2012, Pages 594-600

  Varsavsky, Mariela ^a   Reyes Garcia, Rebeca ^a   Perez, Maria Dolores Avilés ^a   Ramírez, Amanda Rocio Gonzalez ^b   Mijan, Jose Luis ^b   Muñoz Torres, Manuel ^a  

^a Endocrinology Division   (Spain)

^b HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

Author keywords

Androgen deprivation therapy; Opg; Vertebral fractures

Indexed keywords

ESTRADIOL; OSTEOPROTEGERIN; TESTOSTERONE;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE DENSITY; BONE TURNOVER; CANCER HORMONE THERAPY; CANCER PATIENT; CROSS-SECTIONAL STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTRADIOL BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; SPINE FRACTURE; TESTOSTERONE BLOOD LEVEL;

ABSORPTIOMETRY, PHOTON; ANDROGEN ANTAGONISTS; BONE DENSITY; CROSS-SECTIONAL STUDIES; ESTRADIOL; GONADAL STEROID HORMONES; HUMANS; MALE; OSTEOPROTEGERIN; PROSTATIC NEOPLASMS; SPINAL FRACTURES; TESTOSTERONE;

EID: 84866428252     PISSN: 01963635     EISSN: 19394640     Source Type: Journal    
DOI: 10.2164/jandrol.111.014696     Document Type: Article

References (29)

1. Amin S, Zhang Y, Sawin CT, Evans SR, Hannan MT, Kiel DP, Wilson PW, Felson DT. Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham study. Ann Intern Med. 2000;133:951-963.
2. Bolla M, De Reijke TM, Van Tienhoven G, Van der Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G, Kariakine O, van der Steen-Banasik EM, Musat E, Pierart M, Mauer ME, Collette L. Duration of androgen suppression in the treatment of prostate cancer. N Eng J Med. 2009;360:2516-2527.
3. Brown JM, Corey E, Lee ZD, True LD, Yun TJ, Tondravi M, Vesella RL. Osteoprotegerin and osteoclast differentiation factor expression in prostate cancer. Urology. 2001a;57:611-616.
4. Brown JM, Vessella RL, Kostenuik PJ, Dunstan CR, Lange PH, Corey E. Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin Cancer Res. 2001b;7:2977-2983..
5. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab. 2001;86:631-637.
6. Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, Rabbani S. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer. 2006;107:289-298.
7. Eaton CL, Wells JM, Holen I, Croucher PI, Hamdy FC. Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. Prostate. 2004;59:304-310.
8. Fahrleitner-Pammer A, Dobnig H, Piswanger-Soelkner C, Bonelli C, Dimai HP, Leb G, Obermayer Pietsch B. Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover or fracture status. Wien Klin Wochenschr. 2003;115:291-297.
9. Greendale GA, Edelstein S, Barret-Connor E. Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo study. J Bone Miner Res. 1997;12:1833-1843.
10. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab. 2005;90:6410-6417.
11. Holen I, Croucher PI, Hamdy FC, Eaton CL. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res. 2002;62:1619-1623.
12. Indridason OS, Franson L, Sigurdsson G. Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. Osteoporos Int. 2005;16:417-423.
13. Jung K, Lein M, Stephan C, Von Hosslin K, Semjonov A, Sinia P, Loening S, Schnorr D. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer. 2004;111:783-791.
14. Khosla S, Arrighi HM, Melton LJ III, Atkinson EJ, O'Fallon WM, Dunstan C, Riggs BL. Correlates of osteoprotegerin levels in women and men. Osteoporos Int. 2002a;13:394-399.
15. Khosla S, Atkinson EJ, Dunstan CR, O'Fallon WM. Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab. 2002b;87:1550-1554.
16. Khosla S, Melton LJ III, Atkinson EJ, O'Fallon WM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab. 2001;86: 3555-3561.
17. Khosla S, Melton LJ III, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab. 1998;83:2266-2274.
18. Mezquita-Raya P, de la Higuera M, Garcia DF, Alonso G, Ruiz-Requena ME, de Dios Luna JD, Escobar Jimenez F, Muñoz Torres M. The contribution of serum osteoprotegerin on bone mass and vertebral fractures in postmenopausal women. Osteopor Int. 2005;16:1368-1374.
19. Mountzios G, Dimopoulos MA, Bamias A, Papadopoulos G, Kastritis E, Syrigos K, Pavlakis G, Terpos E. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. Acta Oncol. 2007;46:221-229.
20. Narita N, Yuasa T, Tsuchiya N, Kumazawa T, Narita S, Inoue T, Ma Z, Saito M, Horikawa Y, Satoh S, Ogawa O, Habuchi T. A genetic polymorphism of the osteoprotegerin gene is associated with an increased risk of advanced prostate cancer. BMC Cancer. 2008;8:224-232.
21. Penno H, Silfverswärd CJ, Frost A, Brändström H, Nilsson O, Ljunggren O. Osteoprotegerin secretion from prostate cancer is stimulated by cytokines, in vitro. Biochem Biophys Res Commun. 2002;293:451-455.
22. Perkel VS, Mohan S, Herring SJ, Baylink DJ, Linkhart TA. Human prostatic cancer cells, PC3, elaborate mitogenic activity which selectively stimulates human bone cells. Cancer Res. 1990;50:6902-6907.
23. Rogers A, Eastell R. Circulating osteoprotegerin and receptor activator for nuclear factor kB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab. 2005;90:6323-6331.
24. Saika M, Inoue D, Kido S, Matsumoto T. 17-b-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-a. Endocrinology. 2001;142:2205-2212.
25. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Eng J Med. 2005;352:154-164.
26. Södergård R, Bäckström T, Shanbhang V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem. 1982;16:801-810.
27. Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD. Osteoprotegerin serum levels in men: correlation with age, estrogen and testosterone status. J Clin Endocrinol Metab. 2001;86: 3162-3165.
28. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84:3666-3672.
29. Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller T. Osteoprotegerin inhibits prostate cancerinduced osteoclastogenesis and prevents tumor growth in the bone. J Clin Invest. 2001;107:1235-1244.